PURPOSE: Imatinib is currently used for the treatment of chronic myeloid leukemia (CML). The main metabolite CGP74588 has similar potency to that of imatinib and is a product of CYP3A4 and CYP3A5 metabolism. However, the clinical significance of the metabolism on therapeutic response and pharmacokinetics is still unclear. We designed this study to investigate the role of the CYP3A activity in the response to imatinib therapy. METHODS: Fourteen CML patients were phenotyped for in vivo CYP3A activity using quinine as a probe drug. The plasma concentration ratio of quinine and its CYP3A metabolite was used for assessing CYP3A activity. The patients were divided into complete molecular responders with undetectable levels of BCR-ABL transcripts after 12 months of therapy and into partial molecular responders who had failed to achieve a complete molecular response. RESULTS: Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9). CONCLUSIONS: These results indicate a clinical significance of the CYP3A activity and its metabolic products in CML patients treated with imatinib.
PURPOSE:Imatinib is currently used for the treatment of chronic myeloid leukemia (CML). The main metabolite CGP74588 has similar potency to that of imatinib and is a product of CYP3A4 and CYP3A5 metabolism. However, the clinical significance of the metabolism on therapeutic response and pharmacokinetics is still unclear. We designed this study to investigate the role of the CYP3A activity in the response to imatinib therapy. METHODS: Fourteen CMLpatients were phenotyped for in vivo CYP3A activity using quinine as a probe drug. The plasma concentration ratio of quinine and its CYP3A metabolite was used for assessing CYP3A activity. The patients were divided into complete molecular responders with undetectable levels of BCR-ABL transcripts after 12 months of therapy and into partial molecular responders who had failed to achieve a complete molecular response. RESULTS:Patients that achieved complete molecular response showed significantly (Mann-Whitney U-test, p=0.013) higher in vivo CYP3A activity (median quinine metabolic ratio = 10.1) than patients achieving partial molecular response (median = 15.9). CONCLUSIONS: These results indicate a clinical significance of the CYP3A activity and its metabolic products in CMLpatients treated with imatinib.
Authors: Philipp le Coutre; Karl-Anton Kreuzer; Stefan Pursche; Malte v Bonin; Traugott Leopold; Gökben Baskaynak; Bernd Dörken; Gerhard Ehninger; Oliver Ottmann; Andreas Jenke; Martin Bornhäuser; Eberhard Schleyer Journal: Cancer Chemother Pharmacol Date: 2003-12-05 Impact factor: 3.333
Authors: Reginald F Frye; Sara M Fitzgerald; Theodore F Lagattuta; Matthew W Hruska; Merrill J Egorin Journal: Clin Pharmacol Ther Date: 2004-10 Impact factor: 6.875
Authors: Ann E Bolton; Bin Peng; Martine Hubert; Axel Krebs-Brown; Renaud Capdeville; Urs Keller; Michael Seiberling Journal: Cancer Chemother Pharmacol Date: 2003-11-07 Impact factor: 3.333
Authors: Marialuisa Polillo; Sara Galimberti; Claudia Baratè; Mario Petrini; Romano Danesi; Antonello Di Paolo Journal: Int J Mol Sci Date: 2015-09-21 Impact factor: 5.923